380 related articles for article (PubMed ID: 35965963)
1. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.
Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L
Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
3. Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance.
Hoffmann D; Dvorakova T; Schramme F; Stroobant V; Van den Eynde BJ
Front Immunol; 2020; 11():601759. PubMed ID: 33363543
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
6. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
[TBL] [Abstract][Full Text] [Related]
8. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
[TBL] [Abstract][Full Text] [Related]
9. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
[TBL] [Abstract][Full Text] [Related]
10. Heme-containing enzymes and inhibitors for tryptophan metabolism.
Yan D; Lin YW; Tan X
Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
Li Y; Zhang S; Wang R; Cui M; Liu W; Yang Q; Kuang C
Bioorg Med Chem Lett; 2020 Jun; 30(11):127159. PubMed ID: 32247733
[TBL] [Abstract][Full Text] [Related]
12.
Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
[TBL] [Abstract][Full Text] [Related]
13. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
[TBL] [Abstract][Full Text] [Related]
14. Targeting the IDO1 pathway in cancer: from bench to bedside.
Liu M; Wang X; Wang L; Ma X; Gong Z; Zhang S; Li Y
J Hematol Oncol; 2018 Aug; 11(1):100. PubMed ID: 30068361
[TBL] [Abstract][Full Text] [Related]
15. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.
Brochez L; Kruse V; Schadendorf D; Muller AJ; Prendergast GC
Front Immunol; 2021; 12():789473. PubMed ID: 34938297
[No Abstract] [Full Text] [Related]
16. Indoleamine dioxygenase and tryptophan dioxygenase activities are regulated through GAPDH- and Hsp90-dependent control of their heme levels.
Biswas P; Dai Y; Stuehr DJ
Free Radic Biol Med; 2022 Feb; 180():179-190. PubMed ID: 35051612
[TBL] [Abstract][Full Text] [Related]
17. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy.
Austin CJ; Rendina LM
Drug Discov Today; 2015 May; 20(5):609-17. PubMed ID: 25478733
[TBL] [Abstract][Full Text] [Related]
18. Discovery and biological evaluation of tanshinone derivatives as potent dual inhibitors of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase.
Liu J; Ren J; Yang K; Chen S; Yang X; Zhao QS
Eur J Med Chem; 2022 May; 235():114294. PubMed ID: 35358772
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine dioxygenase and tryptophan dioxygenase activities are regulated through control of cell heme allocation by nitric oxide.
Biswas P; Stuehr DJ
J Biol Chem; 2023 Jun; 299(6):104753. PubMed ID: 37116709
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
